Negin Safari Dehnavi

Dr. Negin Safari Dehnavi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 May 2026 in Biology
Verified
Journal Article
Open access
PDF file
RHReza Mosaddeghi Heris
Reza Mosaddeghi Heris
NFNasrin . Forghani
Nasrin . Forghani
NDNegin Safari Dehnavi
Negin Safari Dehnavi
MSMaryam Saberivand
Maryam Saberivand
ATAmir Tahavvori
Amir Tahavvori
PMPaolo Martelletti
Paolo Martelletti
Sensory neurons at barrier tissues were once seen as passive detectors of environmental stimuli. However, in the last five years, increasing evidence has challenged this view, redefining these cells as active immune sentinels that directly affect tissue immunity in the skin, lungs, and gastrointestinal tract. Nociceptors and pruriceptors express various immune-sensing receptors, including Toll-like receptors, cytokine receptors, and alarmin sensors, which allow them to directly detect pathogens, allergens, and tissue damage. When activated, sensory neurons quickly release neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, vasoactive intestinal peptide (VIP), and PACAP (pituitary adenylate cyclase-activating polypeptide), which guide immune cell recruitment, activation, and resolution. Reciprocally, immune-derived mediators, including IL-33, IL-31, thymic stromal lymphopoietin (TSLP), IL-4/IL-13, and TNF-α, modulate neuronal excitability and plasticity, forming bidirectional neuroimmune circuits that control inflammation, host defense, pain, and itch. Landmark studies published in 2024–2025, including neuronal control of gut Treg function and the identification of sensory nerve immune niches, have further refined this framework and revealed tissue-specific circuit specialization. This review synthesizes recent insights from molecular, cellular, and systems levels into the sensory neuroimmune axis, emphasizes its protective versus pathogenic roles, and critically evaluates emerging therapeutic strategies and safety concerns, positioning sensory neuroimmunology as a unifying framework for tissue barrier homeostasis and disease.

23 February 2026 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
MHMohammad Amin Habibi
Mohammad Amin Habibi
SHSeyed Hesam Hojjat
Seyed Hesam Hojjat
BHBardia Hajikarimloo
Bardia Hajikarimloo
MDMohsen Dashti
Mohsen Dashti
AGAfsaneh Ghasemzadeh
Afsaneh Ghasemzadeh
MSMilad Shafizadeh
Milad Shafizadeh
Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown promise in improving survival and managing associated complications. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Anlotinib in patients with high-grade glioma, specifically glioblastoma (GBM). This study was conducted according to the PRISMA guidelines. A systematic search was conducted on PubMed, Embase, Web of Science, and Scopus up to 9 December 2024. The included studies were appraised and assessed for quality and potential bias and further statistical analyses were performed using STATA v.17. A total of 17 studies with 473 patients were recruited, which included 204 patients with GBM. The pooled analysis resulted in a 6-month OS of 67% (95% CI: 42–92%) and a 1-year OS equal to 50% (95% CI: 36–64%) from the Anlotinib treatment. Progression-free survival at 6 months was 61% (95% CI: 46–75%), and at 1 year was 27% (95% CI: 13–41%), also showing similar promising outcomes. The overall response rate (ORR) and disease control rate (DCR) were reported at 55% (95% CI: 44–67%) and 90% (95% CI: 87–94%), respectively. The sub-group analysis revealed that adding anlotinb to temozolomide (TMZ) and radiotherapy had superior outcomes regarding OS, PFS, and DCR. Moreover, the highest ORR and complete response rate were achieved by Anlotinib plus stereotactic radiosurgery. Anlotinib demonstrates considerable efficacy in extending survival and achieving disease control in high-grade glioma patients when added to radiotherapy and TMZ. These findings can support its inclusion in therapeutic regimens, warranting further investigation in large-scale randomized controlled trials.

2 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
FFFarzan Fahim
Farzan Fahim
NDNegin Safari Dehnavi
Negin Safari Dehnavi
MFMohammadAmin Farajzadeh
MohammadAmin Farajzadeh
AVAysan Valinejad
Aysan Valinejad
SHShahriar Heshmaty
Shahriar Heshmaty
SOSayeh Oveisi
Sayeh Oveisi
Background: Middle meningeal artery embolization (MMAE) has emerged as an adjunct or alternative strategy for the management of chronic subdural hematoma (cSDH). Although accumulating studies suggest potential benefit, uncertainty remains regarding its safety profile, recurrence-prevention effect, and the reliability of adverse event reporting. This systematic review and meta-analysis re-evaluate contemporary evidence, incorporating new randomized trials and large observational cohorts. Methods: This systematic review was conducted in accordance with PRISMA 2020 guidelines and prospectively registered in PROSPERO. PubMed, Scopus, Web of Science Core Collection, Embase, and CENTRAL were searched from inception to 12 September 2025 without language restrictions. Randomized controlled trials, prospective or retrospective cohort studies, and non-randomized clinical studies evaluating middle meningeal artery embolization (MMAE) for chronic subdural hematoma were eligible. Data extraction and risk-of-bias assessment were performed independently using Joanna Briggs Institute appraisal tools. Where outcomes were sufficiently comparable, quantitative synthesis was undertaken using random-effects single-arm proportion meta-analysis with logit transformation. Recurrence after MMAE was pooled across observational studies and MMAE arms of randomized trials with available event-level data, with prespecified subgroup analyses by study design. Mortality was synthesized from randomized trials reporting event-level data within a ≤90-day follow-up window. Complication rates and technical success were analyzed descriptively due to heterogeneity in definitions and follow-up durations. Results: Nineteen studies met eligibility criteria, including seven randomized controlled trials, sixteen retrospective cohorts, and one prospective cohort, comprising an elderly and medically complex population (mean ages 61–89 years). Common comorbidities included hypertension, diabetes, cardiovascular and cerebrovascular disease, renal dysfunction, and antithrombotic use. Technical success of middle meningeal artery embolization (MMAE) was consistently high, with a pooled success rate of 100% (95% CI 0.99–1.00; I 2 = 0%). Recurrence after MMAE was consistently low across randomized and observational studies, including high-risk populations, and was uniformly lower than in comparator groups. Radiographic outcomes showed substantial hematoma volume reduction and high rates of complete or near-complete resolution, with favorable functional recovery. Complications were uncommon but heterogeneous; the pooled overall complication rate was 14% (95% CI 0.08–0.21). Pooled 90-day all-cause mortality from randomized trials was 8% (95% CI 0.07–0.10; I 2 = 0%). Conclusion: MMAE is a safe and effective adjunctive or alternative treatment for chronic subdural hematoma, demonstrating a reproducible and clinically meaningful reduction in recurrence across randomized and observational datasets with homogeneous outcome definitions. However, variability in adverse event reporting, insufficient documentation of rare complications, and inconsistent definitions of radiographic versus clinical recurrence highlight the need for standardized outcome frameworks and harmonized follow-up protocols. Future well-designed trials with robust adverse event adjudication are essential to define the long-term safety profile of MMAE and to guide its optimal integration into cSDH management pathways.

6 February 2026 in Neurosurgical Review
Verified
Journal Article
Closed access
AKArmin Khavandegar
Armin Khavandegar
ZRZahra Ramezani
Zahra Ramezani
EKElaheh Khodadoust
Elaheh Khodadoust
MTMahgol Sadat Hassan Zadeh Tabatabaei
Mahgol Sadat Hassan Zadeh Tabatabaei
TMTahereh Maleki
Tahereh Maleki
MSMahdi Sharif-Alhoseini
Mahdi Sharif-Alhoseini

21 April 2026 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
AKAmir Khanmirzaei
Amir Khanmirzaei
NDNegin Safari Dehnavi
Negin Safari Dehnavi
MHMohammad Amin Habibi
Mohammad Amin Habibi
PDPouria Delbari
Pouria Delbari
MAMuhammad-Hussain Ahmadvand
Muhammad-Hussain Ahmadvand
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar